Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia

被引:30
|
作者
Lencer, Rebekka [1 ,2 ]
Sprenger, Andreas [3 ]
Harris, Margret S. H. [1 ]
Reilly, James L. [1 ]
Keshavan, Matcheri S. [4 ]
Sweeney, John A. [1 ]
机构
[1] Univ Illinois, Ctr Cognit Med, Chicago, IL 60612 USA
[2] Med Univ Lubeck, Dept Psychiat & Psychotherapy, D-23538 Lubeck, Germany
[3] Med Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany
[4] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI USA
基金
美国国家卫生研究院;
关键词
D O I
10.1001/archpsyc.65.10.1146
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Context: Analyses of smooth pursuit eye movement parameters in patients with schizophrenia provide information about the integrity of neural networks mediating motion perception, sensorimotor transformation, and cognitive processes such as prediction. Although pursuit eye tracking deficits have been widely reported in schizophrenia, the integrity of discrete components of pursuit responses and the effect of second- generation antipsychotic medication on them are not well established. Objective: To examine different components of smooth pursuit performance in antipsychotic-naive patients with schizophrenia before and after treatment with second-generation antipsychotic medication. Design, Setting, and Participants: Thirty-three antipsychotic-naive patients with schizophrenia performed 3 different smooth pursuit paradigms designed to evaluate specific components of the pursuit response. All of the patients were retested after 6 weeks of treatment with risperidone or olanzapine. Testing was also performed with 39 matched healthy individuals. Thirteen patients and 21 healthy participants were retested after 26 and 52 weeks. Main Outcome Measures: Pursuit initiation, maintenance gain (ratio of eye velocity over target velocity), and frequency of catch-up saccades during pursuit maintenance. Results: Prior to treatment, pursuit gain when tracking less predictable ramp targets tended to be reduced, latency of pursuit initiation was speeded, and catch-up saccade frequency was increased during predictive pursuit. After antipsychotic treatment initiation, pursuit gain decreased with ramp targets, indicating treatment-emergent impairments in sensorimotor processing. No changes were observed for predictive pursuit. Exploratory analyses in the subgroup with follow-up to 1 year revealed that these effects continued through long-term follow-up with some partial normalization at 1 year. Deficits were unrelated to drug dosage and clinical ratings. Conclusions: Impaired sensorimotor function was observed after initiation of second- generation antipsychotic medications, which may be explained by their serotonergic antagonism of brainstem sensorimotor systems. Predictive mechanisms supported by frontostriatal-cerebellar circuitry were not affected by treatment initiation and appear able to compensate for treatment-emergent sensorimotor impairments during predictive tracking.
引用
下载
收藏
页码:1146 / 1154
页数:9
相关论文
共 50 条
  • [41] Neuroanatomical correlates of neurological soft signs in antipsychotic-naive schizophrenia
    Venkatasubramanian, Ganesan
    Jayakumar, Peruvumba. N.
    Gangadhar, Bangalore N.
    Keshavan, Matcheri S.
    PSYCHIATRY RESEARCH-NEUROIMAGING, 2008, 164 (03) : 215 - 222
  • [42] An Automated Parcellation Study of Cerebellar Volume in Antipsychotic-Naive Schizophrenia
    Danivas, Vijay
    Kalmady, Sunil
    Venkatasubramanian, Ganesan
    Gangadhar, Bangalore N.
    BIOLOGICAL PSYCHIATRY, 2012, 71 (08) : 261S - 262S
  • [43] Metabolic Risks in Older Adults Receiving Second-Generation Antipsychotic Medication
    Brooks, John O., III
    Chang, Hye-Sang
    Krasnykh, Olya
    CURRENT PSYCHIATRY REPORTS, 2009, 11 (01) : 33 - 40
  • [44] Metabolic monitoring of pediatric patients prescribed second-generation antipsychotic medication
    Roebuck, Julie Henshaw
    JOURNAL OF CHILD AND ADOLESCENT PSYCHIATRIC NURSING, 2024, 37 (01)
  • [45] Metabolic risks in older adults receiving second-generation antipsychotic medication
    John O. Brooks
    Hye-Sang Chang
    Olya Krasnykh
    Current Psychiatry Reports, 2009, 11 : 33 - 40
  • [46] Effects of second-generation antipsychotic medications treatment: cognitive improvement in Chinese patients with schizophrenia
    Li, Hailing
    Kong, Lingli
    Shen, Qingfeng
    Zhang, Caiyi
    Liang, Guangli
    Zuo, Xiaowei
    Wang, Chengdong
    Li, Bo
    Sun, Xiuyuan
    Wang, Heng
    Zhu, Xianghua
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (02): : 3600 - 3605
  • [47] Akathisia and second-generation antipsychotic drugs
    Kumar, Rajeev
    Sachdev, Perminder S.
    CURRENT OPINION IN PSYCHIATRY, 2009, 22 (03) : 293 - 299
  • [48] Akathisia and second-generation antipsychotic drugs
    Kumar, R.
    Sachdev, P.
    MOVEMENT DISORDERS, 2009, 24 : S67 - S67
  • [49] Akathisia and second-generation antipsychotic drugs
    Kumar, R.
    Sachdev, P. S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S122 - S122
  • [50] First-generation versus second-generation antipsychotic drugs for depression in schizophrenia
    Corbo, M.
    Acciavatti, T.
    Marini, S.
    Cinosi, E.
    Di Tizio, L.
    Di Caprio, L.
    Viceconte, D.
    Matteo, L.
    Giuseppe, D. I.
    Martinotti, G.
    Di Giannantonio, M.
    EUROPEAN PSYCHIATRY, 2016, 33 : S245 - S245